Skip to main content
Top
Published in: International Journal of Clinical Pharmacy 5/2012

01-10-2012 | Commentary

Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention

Authors: Mara Pereira Guerreiro, Ana Paula Martins, Judith Anne Cantrill

Published in: International Journal of Clinical Pharmacy | Issue 5/2012

Login to get access

Abstract

This commentary relates to a paper on the development and piloting of a risk management intervention in Portuguese community pharmacy, based on validated preventable drug-related morbidity indicators. In the paper we presented the research programme and implications for future evaluation. However, we believe that the intervention may be seen as important for patient safety without further evaluation. Therefore in this commentary we discuss considerations for service roll-out, by revisiting some issues already presented and by introducing aspects such as service definition and remuneration. We argue that in the absence of service remuneration, redesign of care processes through IT support and inter-professional collaboration, and coaching to encourage the aforementioned efforts it is unlikely that the proposed risk management intervention will succeed in preventing drug-related morbidity.
Literature
1.
go back to reference Guerreiro MP, Martins AP, Cantrill JA. Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention. Int J Clin Pharm. 2012; published on-line. doi:10.1007/s11096-012-9625-3. Guerreiro MP, Martins AP, Cantrill JA. Preventable drug-related morbidity in community pharmacy: development and piloting of a complex intervention. Int J Clin Pharm. 2012; published on-line. doi:10.​1007/​s11096-012-9625-3.
2.
go back to reference Leape LL, Berwick D, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002;288:501–7.PubMedCrossRef Leape LL, Berwick D, Bates DW. What practices will most improve safety? Evidence-based medicine meets patient safety. JAMA. 2002;288:501–7.PubMedCrossRef
3.
go back to reference Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–19. Avery AJ, Rodgers S, Cantrill JA, Armstrong S, Cresswell K, Eden M, Elliott RA, et al. A pharmacist-led information technology intervention for medication errors (PINCER): a multicentre, cluster randomised, controlled trial and cost-effectiveness analysis. Lancet. 2012;379(9823):1310–19.
4.
go back to reference Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL. Monitoring statin safety in primary care. Pharmacoepidemiol Drug Safety. 2007;16:652–7.CrossRef Tragni E, Filippi A, Mazzaglia G, Sessa E, Cricelli C, Catapano AL. Monitoring statin safety in primary care. Pharmacoepidemiol Drug Safety. 2007;16:652–7.CrossRef
5.
go back to reference Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Safety. 2007;16:55–64.CrossRef Raebel MA, McClure DL, Simon SR, Chan KA, Feldstein A, Andrade SE, et al. Laboratory monitoring of potassium and creatinine in ambulatory patients receiving angiotensin converting enzyme inhibitors and angiotensin receptor blockers. Pharmacoepidemiol Drug Safety. 2007;16:55–64.CrossRef
6.
go back to reference Vainio KK, Airaksinen MS, Hyykky TT, Enlund KH. Effect of therapeutic class on counselling in community pharmacies. Ann Pharmacother. 2002;36:781–6.PubMedCrossRef Vainio KK, Airaksinen MS, Hyykky TT, Enlund KH. Effect of therapeutic class on counselling in community pharmacies. Ann Pharmacother. 2002;36:781–6.PubMedCrossRef
7.
go back to reference Horne R, Hankins M, Jenkins R. The satisfaction with information about medicines scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10:135–40.PubMedCrossRef Horne R, Hankins M, Jenkins R. The satisfaction with information about medicines scale (SIMS): a new measurement tool for audit and research. Qual Health Care. 2001;10:135–40.PubMedCrossRef
8.
go back to reference Astrom K, Carlsson J, Bates I, Webb DG, Duggan C, Sanghani P, et al. Desire for information about drugs: a multi-method study in general medicine patients. Pharm World Sci. 2000;22:159–64.PubMedCrossRef Astrom K, Carlsson J, Bates I, Webb DG, Duggan C, Sanghani P, et al. Desire for information about drugs: a multi-method study in general medicine patients. Pharm World Sci. 2000;22:159–64.PubMedCrossRef
9.
go back to reference Costa FA, Duggan C, Bates I. Validation of a survey tool for use in cross-cultural studies. Pharmacy Practice. 2008;6:121–7. Costa FA, Duggan C, Bates I. Validation of a survey tool for use in cross-cultural studies. Pharmacy Practice. 2008;6:121–7.
10.
go back to reference Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13:181–5.PubMedCrossRef Morris CJ, Rodgers S, Hammersley VS, Avery AJ, Cantrill JA. Indicators for preventable drug related morbidity: application in primary care. Qual Saf Health Care. 2004;13:181–5.PubMedCrossRef
11.
go back to reference MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP 2003; 9:134–41. MacKinnon NJ, Hepler CD. Preventable drug-related morbidity in older adults—2. Use within a managed care organisation. JMCP 2003; 9:134–41.
12.
go back to reference Government Decree no. 112/2011, 29th November (Decreto-Lei no 112/2011, 29 de Novembro). Government Decree no. 112/2011, 29th November (Decreto-Lei no 112/2011, 29 de Novembro).
13.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. Int J Pharm Pract. 2006;14:163–70.CrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Implementing cognitive services in community pharmacy: a review of facilitators used in practice change. Int J Pharm Pract. 2006;14:163–70.CrossRef
14.
go back to reference Ministerial Order no. 301/2008, 18th April (Portaria no 301/2008, de 18 de Abril). Ministerial Order no. 301/2008, 18th April (Portaria no 301/2008, de 18 de Abril).
15.
go back to reference Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008;42:861–8.PubMedCrossRef Roberts AS, Benrimoj SI, Chen TF, Williams KA, Aslani P. Practice change in community pharmacy: quantification of facilitators. Ann Pharmacother. 2008;42:861–8.PubMedCrossRef
16.
go back to reference Shah NR, Seger AC, Seger D, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK. Improving acceptance of computerized prescribing alerts in ambulatory care. JAMIA 2006; 13: 5–11. Shah NR, Seger AC, Seger D, Fiskio JM, Kuperman GJ, Blumenfeld B, Recklet EG, Bates DW, Gandhi TK. Improving acceptance of computerized prescribing alerts in ambulatory care. JAMIA 2006; 13: 5–11.
17.
go back to reference Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606. Paulino EI, Guerreiro MP, Cantrill JA, Martins AP, Costa FA, Benrimoj SI. Community pharmacists’ and physicians’ inter-professional work—insights from qualitative studies with multiple stakeholders. Rev Port Clin Geral. 2010;26:590–606.
18.
go back to reference Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs in innovative clinical services—a conceptual model. J Soc Adm Pharm. 1999;16:134–43. Chen TF, Crampton M, Krass I, Benrimoj SI. Collaboration between community pharmacists and GPs in innovative clinical services—a conceptual model. J Soc Adm Pharm. 1999;16:134–43.
19.
go back to reference Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63:136–47.PubMedCrossRef Howard RL, Avery AJ, Slavenburg S, Royal S, Pipe G, Lucassen P, et al. Which drugs cause preventable hospital admissions to hospital? A systematic review. Br J Clin Pharmacol. 2006;63:136–47.PubMedCrossRef
20.
go back to reference Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411–26.PubMedCrossRef Thomsen LA, Winterstein AG, Søndergaard B, Haugbølle LS, Melander A. Systematic review of the incidence and characteristics of preventable adverse drug events in ambulatory care. Ann Pharmacother. 2007;41:1411–26.PubMedCrossRef
21.
go back to reference Schnipper JL, Rothschild JM. Improving medication safety. Lancet. 2012;379(9823):1278–80. Schnipper JL, Rothschild JM. Improving medication safety. Lancet. 2012;379(9823):1278–80.
Metadata
Title
Preventable drug-related morbidity in community pharmacy: commentary on the implications for practice and policy of a novel intervention
Authors
Mara Pereira Guerreiro
Ana Paula Martins
Judith Anne Cantrill
Publication date
01-10-2012
Publisher
Springer Netherlands
Published in
International Journal of Clinical Pharmacy / Issue 5/2012
Print ISSN: 2210-7703
Electronic ISSN: 2210-7711
DOI
https://doi.org/10.1007/s11096-012-9669-4

Other articles of this Issue 5/2012

International Journal of Clinical Pharmacy 5/2012 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine